Literature DB >> 27978764

National Study of Muscle Cramps in ALS in the USA.

Helen E Stephens1, Nanette C Joyce2, Björn Oskarsson1.   

Abstract

The objective of this study was to describe muscle cramps in an US sample of amyotrophic lateral sclerosis (ALS) patients. Utilizing an anonymous web based questionnaire we queried ALS patients regarding the severity, frequency, time-course, treatment of muscle cramps and their relationship to pain. The survey had 282 respondents with 92% reporting that they had cramps. For 20% of the sample, cramps were stated to be the presenting ALS symptom. Cramp severity was rated at a mean of 5.2/10 and the mean cramp frequency was 5.3 cramps per day. Cramp intensity and frequency did not correlate with duration or severity of ALS. Pain as measured with the Patient Reported Outcome Measurement Information System (PROMIS) pain scales was not statistically different from the US general population. Cramp severity and frequency significantly and positively correlated with the PROMIS pain scales. Patients with more severe cramps were more likely to use prescription medications for their cramps compared to patients with milder symptoms. Treatments directed at cramps were tried by 57%. In conclusion, cramps are a common symptom in ALS and it does not correlate with disease duration or severity. The severity of cramps is on average moderate and many patients try treatments.

Entities:  

Keywords:  Cramp; patient reported outcome; questionnaire

Mesh:

Substances:

Year:  2016        PMID: 27978764      PMCID: PMC5575819          DOI: 10.1080/21678421.2016.1245755

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  17 in total

1.  A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.

Authors:  Michael D Weiss; Eric A Macklin; Zachary Simmons; Angela S Knox; David J Greenblatt; Nazem Atassi; Michael Graves; Nicholas Parziale; Johnny S Salameh; Colin Quinn; Robert H Brown; Jane B Distad; Jaya Trivedi; Jeremy M Shefner; Richard J Barohn; Alan Pestronk; Andrea Swenson; Merit E Cudkowicz
Journal:  Neurology       Date:  2016-02-24       Impact factor: 9.910

2.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.

Authors:  David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays
Journal:  J Clin Epidemiol       Date:  2010-08-04       Impact factor: 6.437

3.  The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes.

Authors:  J F Fries; B Bruce; D Cella
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

4.  EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.

Authors:  Peter M Andersen; Sharon Abrahams; Gian D Borasio; Mamede de Carvalho; Adriano Chio; Philip Van Damme; Orla Hardiman; Katja Kollewe; Karen E Morrison; Susanne Petri; Pierre-Francois Pradat; Vincenzo Silani; Barbara Tomik; Maria Wasner; Markus Weber
Journal:  Eur J Neurol       Date:  2011-09-14       Impact factor: 6.089

5.  The role of mental health and self-efficacy in the pain experience of patients with amyotrophic lateral sclerosis.

Authors:  Helen E Stephens; Erik Lehman; Divisha Raheja; Chengwu Yang; Susan Walsh; Zachary Simmons
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-02-15       Impact factor: 4.092

6.  Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial.

Authors:  M Weber; B Goldman; S Truniger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-05-24       Impact factor: 10.154

7.  The natural history of amyotrophic lateral sclerosis.

Authors:  S P Ringel; J R Murphy; M K Alderson; W Bryan; J D England; R G Miller; J H Petajan; S A Smith; R I Roelofs; F Ziter
Journal:  Neurology       Date:  1993-07       Impact factor: 9.910

8.  Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability.

Authors:  Elsa Fritz; Pamela Izaurieta; Alexandra Weiss; Franco R Mir; Patricio Rojas; David Gonzalez; Fabiola Rojas; Robert H Brown; Rodolfo Madrid; Brigitte van Zundert
Journal:  J Neurophysiol       Date:  2013-03-13       Impact factor: 2.714

9.  Leg symptoms in outpatient veterans.

Authors:  S K Oboler; A V Prochazka; T J Meyer
Journal:  West J Med       Date:  1991-09

10.  Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons.

Authors:  Brian J Wainger; Evangelos Kiskinis; Cassidy Mellin; Ole Wiskow; Steve S W Han; Jackson Sandoe; Numa P Perez; Luis A Williams; Seungkyu Lee; Gabriella Boulting; James D Berry; Robert H Brown; Merit E Cudkowicz; Bruce P Bean; Kevin Eggan; Clifford J Woolf
Journal:  Cell Rep       Date:  2014-04-03       Impact factor: 9.423

View more
  4 in total

1.  Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial.

Authors:  Björn Oskarsson; Dan Moore; Tahseen Mozaffar; John Ravits; Martina Wiedau-Pazos; Nicholas Parziale; Nanette C Joyce; Ross Mandeville; Namita Goyal; Merit E Cudkowicz; Michael Weiss; Robert G Miller; Craig M McDonald
Journal:  Muscle Nerve       Date:  2018-03-06       Impact factor: 3.217

2.  Open-label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis.

Authors:  Swathy Chandrashekhar; Anai C Hamasaki; Rebecca Clay; Ayla McCalley; Laura Herbelin; Mamatha Pasnoor; Omar Jawdat; Mazen M Dimachkie; Richard J Barohn; Jeffrey Statland
Journal:  Muscle Nerve       Date:  2022-05-11       Impact factor: 3.852

3.  Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015.

Authors:  Jaime Raymond; BjÖrn Oskarsson; Paul Mehta; Kevin Horton
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-05-26       Impact factor: 4.092

4.  Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives.

Authors:  Matthias Boentert
Journal:  Nat Sci Sleep       Date:  2019-08-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.